AVITA Medical, Inc.

AVITA Medical, Inc. announced an investor webinar briefing and presentation scheduled for August 12, 2026, at 4:00 p.m. Pacific Time. President and CEO Cary Vance and CFO David O’Toole will present financial and business results from the second-quarter 2026 earnings webcast. The event will include a Q&A session, and a replay will be available on the company's website.

AVITA Medical, Inc. announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston, scheduled for August 11–13, 2026. President and CEO Cary Vance is slated to speak on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible via the company's investor relations website, and investors attending the conference can arrange one-on-one meetings with AVITA Medical representatives.

AVITA Medical, Inc. reported its Q2 2026 financial results, with the auditor and management expressing substantial doubt about the company's ability to continue as a going concern for the next twelve months. Despite this, the company secured a new $60 million senior secured credit facility, with $50 million funded, and repaid its previous credit agreement. For the second quarter of 2026, total revenues increased to $21.7 million, and the net loss decreased to $7.7 million compared to the same period last year.

AVITA Medical reported strong financial results for the second quarter ended June 30, 2026, with net revenue reaching a record $21.7 million, an 18% increase year-over-year. The company also raised its full-year 2026 net revenue guidance to a range of $86 million to $89 million, reflecting confidence in continued commercial execution. Additionally, AVITA Medical anticipates achieving cash flow breakeven in the fourth quarter of 2026, driven by disciplined operating expenses and sustained high gross margins. The Centers for Medicare & Medicaid Services (CMS) also proposed favorable 2027 Medicare payment updates for RECELL.

AVITA Medical, Inc. announced it will release its second quarter 2026 financial results after the U.S. financial markets close on Thursday, August 6, 2026. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time to discuss the results and recent business highlights. A replay of the webcast will be available on the investor relations website for those unable to attend the live broadcast.

AVITA Medical announced successful clinical data for its RECELL GO automated system in the U.K., presented at the British Burn Association Annual Meeting. The first U.K. case series involved 17 burn and reconstructive surgery patients, demonstrating successful use, uncomplicated donor-site healing, complete graft take, and improved operating room workflow. This marks an important milestone in the global adoption of RECELL GO, which is CE-marked in Europe and the U.K., and recently authorized in Australia and New Zealand.

AVITA Medical, Inc. issued a warrant certificate to Perceptive Credit Holdings V, LP on June 5, 2026, following stockholder approval at its Annual Meeting on June 3, 2026. This warrant allows Perceptive to purchase up to an initial 500,000 shares of the company's common stock at an exercise price of $3.4019 per share. The warrant is part of a previously disclosed $60 million senior secured credit facility agreement, with an additional 150,000 shares vesting if the company draws an optional $10 million commitment.

AVITA Medical, Inc. held its 2026 Annual Meeting of Stockholders, where all seven directors were re-elected to the Board of Directors. Stockholders also ratified Grant Thornton LLP as the independent registered public accounting firm for 2026. Key approvals included an increase in the aggregate annual cash fee pool for non-executive directors from $750,000 to $900,000, and the issuance of annual and initial equity awards (restricted stock units and stock options) to non-executive directors.

AVITA Medical, Inc. invites shareholders and investors to an investor webinar briefing on May 20, 2026, to discuss financial and business results from its recent first quarter 2026 earnings webcast. The webinar will feature presentations by CEO Cary Vance and CFO David O O Toole, concluding with a Q&A session. Additionally, the company will host an armchair investor discussion in Melbourne, Australia, on May 21, 2026, with CEO Cary Vance, focusing on the company's integrated portfolio, commercial progress, and 2026 execution priorities.

AVITA Medical, Inc. reported its first-quarter 2026 financial results, showing a net loss of $(10.6) million and total revenues of $19.3 million. Despite an improvement in net loss and operating loss compared to the prior year, management expressed substantial doubt about the company's ability to continue as a going concern over the next twelve months due to recurring losses and debt obligations. The company recently secured a new $60.0 million credit facility, which included refinancing previous debt and lowering its minimum cash balance covenant.